Evaluate launches success assessment platform for drug developers

By Vassia Barba

- Last updated on GMT

(Image: Getty/solarseven)
(Image: Getty/solarseven)

Related tags Evaluate machine learning Data management regulatory approval

Product Specific PTRS, Evaluate’s machine learning platform, aims to help assess the likelihood of a drug reaching the market – managing the risks of drug development.

London, UK-headquartered Evaluate, a company providing software services for researchers and drug developers, has released Product Specific PTRS (probability of technical and regulatory success), a platform which processes data to predict a drug’s probability of success.

According to the company, the product identifies ‘the exact attributes’ that are improving or degrading the risk profile of a product in every stage of the development process, and ranks these attributes in order of importance. 

The platform covers data and insights from all new molecular entity (NME) and new drug applications (NDA) and uses machine learning to analyze over 50 drug, company, and market attributes as well as more than 30,000 phase transitions.

Product Specific PTRS is integrated with EvaluatePharma Vision, the company’s subscription service which provides data including the net present value, R&D costs, clinical timelines, and sales forecasts.

The platform is expected to support companies managing clinical portfolios “in light of rising development costs and increased pricing concerns,”​ said Deborah Kobewka, CEO of Evaluate.

According to Kobewka, only 51% of clinical products in Phase III obtain FDA approval, and, due to the significant costs of development programs and clinical studies, “drugmakers are under more pressure than ever to make sound, evidence-based decisions on how to invest in their pipelines.”

Related news

Show more

Related products

show more

Saama accelerates data review processes

Saama accelerates data review processes

Content provided by Saama | 25-Mar-2024 | Infographic

In this new infographic, learn how Saama accelerates data review processes. Only Saama has AI/ML models trained for life sciences on over 300 million data...

More Data, More Insights, More Progress

More Data, More Insights, More Progress

Content provided by Saama | 04-Mar-2024 | Case Study

The sponsor’s clinical development team needed a flexible solution to quickly visualize patient and site data in a single location

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us


View more